CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

Br J Cancer. 2009 Mar 24;100(6):918-22. doi: 10.1038/sj.bjc.6604953. Epub 2009 Feb 24.


CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Female
  • Humans
  • Hyaluronan Receptors / analysis
  • Hyaluronan Receptors / immunology
  • Hyaluronan Receptors / physiology*
  • Mammary Neoplasms, Experimental / chemistry
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / pathology
  • Mice
  • Neoplasm Recurrence, Local / prevention & control*
  • Xenograft Model Antitumor Assays


  • Antibodies, Monoclonal
  • Cd44 protein, mouse
  • Hyaluronan Receptors